LILRC1 Activators
Lilra5, belonging to the leukocyte immunoglobulin-like receptor family, emerges as a crucial modulator of immune responses with its predicted inhibitory MHC class I receptor activity. Positioned on the cell surface and in the extracellular space, Lilra5 plays a pivotal role in immune regulation, contributing to processes such as positive regulation of the MAPK cascade, positive regulation of protein tyrosine kinase activity, and regulation of cytokine production. Its expression in specific tissues, including ganglia, medulla oblongata basal plate mantle layer, and ventral grey horn, further underscores its involvement in diverse cellular environments. Lilra5's influence on key cellular processes positions it as an orchestrator of immune responses, contributing to the dynamic regulation of signaling pathways crucial for maintaining immune homeostasis.
The activation of Lilra5 is a nuanced process involving intricate molecular interactions and signaling cascades. The inhibitory MHC class I receptor activity, a predicted function of Lilra5, suggests its role in dampening immune responses, possibly by modulating interactions between immune cells and MHC class I molecules. The positive regulation of the MAPK cascade, influenced by various signaling molecules, reflects Lilra5's sensitivity to external stimuli and its active participation in cellular responses to environmental changes. Additionally, the positive regulation of protein tyrosine kinase activity suggests Lilra5's involvement in modulating tyrosine phosphorylation dynamics, which can further impact immune signaling pathways. The regulation of cytokine production highlights Lilra5's potential to influence the immune microenvironment by modulating the secretion of signaling molecules involved in immune responses. Overall, Lilra5's activation mechanisms underscore its versatile role in immune regulation, influencing diverse cellular processes. The interconnected signaling pathways and molecular interactions that govern Lilra5 activation showcase its adaptability in responding to various stimuli and cellular contexts. The fine-tuned control exerted by Lilra5 on immune processes contributes to the intricate balance required for maintaining immune homeostasis, emphasizing its significance in shaping the immune landscape. Understanding Lilra5 and its activation mechanisms provides valuable insights into the complexity of immune regulation and opens avenues for further exploration of its role in various physiological and pathological contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine activates Lilra5 by promoting protein tyrosine kinase activity. As a broad-spectrum kinase inhibitor, it enhances the overall tyrosine phosphorylation status, indirectly amplifying Lilra5's inhibitory MHC class I receptor activity. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin stimulates Lilra5 by positively regulating the MAPK cascade. Its activation of p38 and JNK pathways indirectly enhances Lilra5 expression, providing a molecular link between MAPK activation and the upregulation of the inhibitory MHC class I receptor activity. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
Sodium orthovanadate activates Lilra5 by inhibiting protein tyrosine phosphatases. By maintaining elevated tyrosine phosphorylation levels, it indirectly upregulates Lilra5's inhibitory MHC class I receptor activity, establishing a connection between phosphatase inhibition and Lilra5 activation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA stimulates Lilra5 through the activation of protein kinase C (PKC). The downstream signaling cascade positively regulates the MAPK pathway, indirectly promoting Lilra5's inhibitory MHC class I receptor activity, highlighting the role of PKC in orchestrating Lilra5 activation. | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
LPS activates Lilra5 by regulating cytokine production. Its stimulation of TLR4 initiates downstream signaling cascades, influencing cytokine release and indirectly modulating Lilra5 expression. The intricate interplay between immune response and Lilra5 activation reflects its involvement in cytokine regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, influences Lilra5 activation by modulating the p38 MAPK pathway. Its inhibition alleviates suppressive influences on Lilra5, leading to increased expression and highlighting the intricate relationship between p38 MAPK and Lilra5 regulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin activates Lilra5 by inhibiting PI3K. PI3K inhibition disrupts downstream signaling, indirectly influencing Lilra5 expression and providing a molecular link between PI3K activity and the modulation of inhibitory MHC class I receptor activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, a MEK inhibitor, influences Lilra5 activation by dampening the MAPK pathway. Its inhibitory effect on MEK attenuates MAPK signaling, indirectly impacting Lilra5 expression and underscoring the significance of MAPK regulation in Lilra5 activation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, activates Lilra5 by promoting histone acetylation. Enhanced accessibility of the Lilra5 gene results in increased transcription, highlighting the role of epigenetic modifications in shaping Lilra5 expression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib activates Lilra5 by influencing protein tyrosine kinase activity. Its multitargeted kinase inhibition indirectly upregulates Lilra5's inhibitory MHC class I receptor activity, reflecting the intricate modulation of tyrosine phosphorylation in Lilra5 activation. | ||||||